Fuchs Endothelial Corneal Dystrophy Market Forecast Highlights Significant Growth During the Forecast Period (2026-2036), Owing to the Expanding Treatment Landscape and Increasing Patient Pool | DelveInsight
The Fuchs endothelial corneal dystrophy market is expected to witness steady growth over the coming years, driven by the rising prevalence of the disease, an aging global population, and increasing awareness of corneal disorders. Additionally, the expected launch of emerging therapies such as Ripasudil (K-321) (Kowa Pharmaceuticals), TTHX1114 (Trefoil Therapeutics), STN1010904/AE-001 (sirolimus) (Santen/ActualEyes), DT-168 (Design Therapeutics), and others will further propel the market growth.
LAS VEGAS, July 6, 2026 /PRNewswire/ -- Recently published Fuchs Endothelial Corneal Dystrophy Market Insights report includes a comprehensive understanding of current treatment practices, Fuchs endothelial corneal dystrophy emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Fuchs Endothelial Corneal Dystrophy Market Summary
Discover the Fuchs endothelial corneal dystrophy marketed and pipeline drugs analysis @ https://www.delveinsight.com/report-store/fuchs-endothelial-corneal-dystrophy-fecd-market
Key Factors Driving the Growth of the Fuchs Endothelial Corneal Dystrophy Market
Aparna Thakur, assistant project manager of forecasting at DelveInsight, said that the emerging therapies targeting endothelial cell regeneration, oxidative stress, and corneal edema are expected to address substantial unmet needs and expand the treatable patient pool.
Fuchs Endothelial Corneal Dystrophy Market Analysis
Fuchs Endothelial Corneal Dystrophy Competitive Landscape
Some of the FECD drugs under development include Ripasudil (K-321) (Kowa Pharmaceuticals), TTHX1114 (Trefoil Therapeutics), STN1010904/AE-001 (sirolimus) (Santen/ActualEyes), DT-168 (Design Therapeutics), and others.
Kowa Pharmaceuticals' Ripasudil (K-321) is a selective Rho-associated protein kinase (ROCK) inhibitor designed to reduce intraocular pressure (IOP) by enhancing aqueous humor drainage through the conventional outflow pathway. ROCK plays a key role in regulating cellular morphology, contractility, and motility across various tissues, including ocular structures. By promoting the depolymerization of intracellular actin filaments within the trabecular meshwork (TM) and Schlemm's canal (SC), Ripasudil facilitates improved aqueous outflow and consequently lowers IOP. In addition, ROCK inhibition reduces extracellular matrix deposition in TM cells, offering a complementary mechanism that may support long-term IOP control. Ripasudil is currently being evaluated in Phase III clinical trials for the treatment of Fuchs endothelial corneal dystrophy (FECD).
Trefoil Therapeutics' TTHX1114 is an engineered variant of fibroblast growth factor-1 (eFGF-1) developed by Trefoil Therapeutics to safeguard corneal endothelial cells from injury and stress while promoting visual recovery through enhanced cellular proliferation and migration. The development of TTHX1114 has been supported extensively by the National Institutes of Health (NIH) through its Therapeutics for Rare and Neglected Diseases Program. Positive results from the Phase II STORM trial demonstrated that TTHX1114 facilitated corneal regeneration and improved vision following Descemet stripping only (DSO) surgery. In addition, Trefoil is advancing a topical formulation of TTHX1114 aimed at stimulating corneal epithelial cell growth, which may help mitigate complications associated with corneal ulcerative diseases, including inflammation, pain, corneal scarring, and vision impairment.
Santen/ActualEyes' STN1010904 (sirolimus; AE-001) is an ophthalmic suspension intended for the treatment of FECD. As an mTOR inhibitor, the sirolimus-based eye drop is designed to prevent the formation of collagenous deposits (guttae) on the corneal endothelial surface and reduce endothelial cell apoptosis, two hallmark features of FECD. By limiting corneal edema, the therapy aims to preserve corneal transparency and maintain visual function. Through their collaboration, Santen and ActualEyes seek to accelerate the availability of this treatment option and improve the quality of life for patients with FECD. The candidate is currently being investigated in Phase IIa clinical studies.
The anticipated launch of these emerging therapies are poised to transform the Fuchs endothelial corneal dystrophy market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Fuchs endothelial corneal dystrophy market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the TTHX1114 Fuchs endothelial corneal dystrophy clinical trial united kingdom @ TTHX1114 Fuchs Endothelial Corneal Dystrophy UK Site
What is Fuchs Endothelial Corneal Dystrophy?
Fuchs endothelial corneal dystrophy (FECD) is a progressive, inherited eye disorder characterized by the gradual degeneration of endothelial cells in the cornea, the transparent front layer of the eye. These specialized cells are responsible for maintaining corneal clarity by regulating fluid balance within the corneal tissue. As endothelial cells are lost over time, excess fluid accumulates in the cornea, leading to corneal swelling, thickening, and impaired vision. Patients typically experience symptoms such as blurred or hazy vision, glare, increased sensitivity to light, and difficulty seeing in the morning, with symptoms often worsening as the disease progresses. FECD primarily affects adults over the age of 50 and is more common in women than men. In advanced stages, persistent corneal edema can cause pain and significant visual impairment, often necessitating surgical interventions such as endothelial keratoplasty or corneal transplantation to restore vision.
Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation
The Fuchs endothelial corneal dystrophy epidemiology section provides insights into the historical and current Fuchs endothelial corneal dystrophy patient pool and forecasted trends for the leading markets. In 2025, the United States accounted for the highest proportion of diagnosed prevalent cases of FECD (approximately 6.6 million) throughout the 7MM.
The Fuchs endothelial corneal dystrophy treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Fuchs Endothelial Corneal Dystrophy Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Fuchs Endothelial Corneal Dystrophy Epidemiology Segmentation
Total Diagnosed Prevalent Cases of FECD, Age-specific Diagnosed Prevalent Cases of FECD, Total Diagnosed Prevalent Cases of FECD by Grade, Gender-specific Diagnosed Prevalent Cases of FECD, and Total Treated Cases of FECD
Key Fuchs Endothelial Corneal Dystrophy Companies
Kowa Pharmaceuticals, Trefoil Therapeutics, Santen, ActualEyes, Design Therapeutics, and others
Key Fuchs Endothelial Corneal Dystrophy Therapies
Ripasudil (K-321), TTHX1114, STN1010904/AE-001 (sirolimus), DT-168, and others
Scope of the Fuchs Endothelial Corneal Dystrophy Market Report
Download the report to understand Fuchs endothelial corneal dystrophy point prevalence per 100,000 @ Fuchs Endothelial Corneal Dystrophy Drugs
Table of Contents
1
Fuchs Endothelial Corneal Dystrophy Market Key Insights
2
Fuchs Endothelial Corneal Dystrophy Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Methodology
6
FECD Market Overview at a Glance
6.1
Emerging Therapies Analysis (By Phase, RoA, and Molecule Type)
6.2
Market Share by Therapies (%) Distribution of FECD in 2025 in the 7MM
6.3
Market Share by Therapies (%) Distribution of FECD in 2036 in the 7MM
7
Disease Background and Overview
7.1
Introduction
7.2
Types of Corneal Dystrophies
7.3
Clinical Manifestations
7.4
Signs and Symptoms
7.5
Risk Factors
7.6
Genetics and Inheritance
7.7
Pathogenesis
7.8
Prognosis
7.9
Staging
7.10
Diagnosis
8
Epidemiology and Patient Population
8.1
Key Findings
8.2
Assumptions and Rationale: The 7MM
8.2.1
Total Diagnosed Prevalent Cases of FECD
8.2.2
Gender-specific Cases of FECD
8.2.3
Age-specific Cases of FECD
8.2.4
Grade-specific Cases of FECD
8.3
Total Diagnosed Prevalent Cases of FECD in the 7MM
8.4
The US
8.4.1
Total Diagnosed Prevalent Cases of FECD in the US
8.4.2
Gender-specific Cases of FECD in the US
8.4.3
Age-specific Cases of FECD in the US
8.4.4
Grade-specific Cases of FECD in the US
8.4.5
Total Treated Cases of FECD in the US
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey
10
Emerging FECD Drugs
10.1
Key Cross Competition
10.2
Ripasudil (K-321): Kowa Pharmaceuticals
10.2.1
Product Description
10.2.2
Other development activities
10.2.3
Clinical development
10.2.4
Clinical trials information
10.2.5
Safety and Efficacy
10.2.6
Analyst views
10.3
TTHX 1114: Trefoil Therapeutics
10.4
STN1010904/AE-001 (sirolimus): Santen and ActualEyes
To be continued in the report…
11
FECD Market: 7MM Analysis
11.1
Key Findings
11.2
Fuchs Endothelial Corneal Dystrophy Market Outlook
11.3
Conjoint Analysis
11.4
Key Market Forecast Assumptions
11.5
Total Market Size of FECD in the 7MM
11.6
Total Market Size of FECD by Therapies in 7MM
11.7
The United States Fuchs Endothelial Corneal Dystrophy Market Size
11.7.1
Total Market Size of FECD in the United States
11.7.2
Total Market Size of FECD by Therapies in the United States
11.8
EU4 and the UK Fuchs Endothelial Corneal Dystrophy Market Size
11.9
Japan Fuchs Endothelial Corneal Dystrophy Market Size
12
KOL Views
13
Fuchs Endothelial Corneal Dystrophy Market SWOT Analysis
14
Fuchs Endothelial Corneal Dystrophy Market Unmet Needs
15
Market Access and Reimbursement
15.1
The United States
15.2
EU4 and the UK
15.3
Japan
16
Bibliography
17
Acronyms and Abbreviations
18
Fuchs Endothelial Corneal Dystrophy Market Report Methodology
Related Reports
Fuchs Endothelial Corneal Dystrophy Clinical Trial Analysis
Fuchs Endothelial Corneal Dystrophy Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key FECD companies, including Trefoil Therapeutics, Kowa Pharmaceutical, Santen Pharmaceutical, and others.
Presbyopia Market
Presbyopia Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key presbyopia companies including Opus Genetics, Viatris, Eyenovia, Glaukos Corporation, LinkoCare Life Sciences AB, RegenSight, AbbVie, Orasis Pharmaceuticals, LENZ Therapeutics, Tenpoint Therapeutics, and others.
Presbyopia Clinical Trial Analysis Pipeline
Presbyopia Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key presbyopia companies, including Orasis Pharmaceuticals, Novartis, Cellix Bio, Visus Therapeutics, AbbVie, Vyluma, Lenz Therapeutics, Ocuphire Pharma, JIXING Pharmaceuticals, Eyenovia, and others.
Bullous Keratopathy Market
Bullous Keratopathy Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key bullous keratopathy companies including Trefoil Therapeutics, Emmecell, Cellusion, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
SOURCE DelveInsight Business Research, LLP